UniQure Announces Proposed Public Offering; No Size Or Amount Disclosed
UniQure Announces Proposed Public Offering; No Size Or Amount Disclosed
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced an underwritten public offering of its ordinary shares and pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to 15% additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
uniQure N.V.（納斯達克：QURE）是一家領先的基因治療公司，致力於爲具有嚴重醫療需求的患者提供變革性療法，今天宣佈已開始公開承銷其普通股和預先融資的Warrants。所有將在此次發行中出售的證券將由uniQure提供。此外，uniQure打算授予承銷商在公開發行價格基礎上，減去承銷折扣和佣金，購買最多15%額外普通股的30天選擇權。此次發行受市場及其他條件的限制，無法保證是否或何時會完成發行，或實際的發行規模或條款。
Leerink Partners is acting as the bookrunning manager for the proposed offering.
Leerink Partners擔任此次擬議發行的圖書管理經理。
譯文內容由第三人軟體翻譯。
